Literature DB >> 21351200

Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia.

Rajan K Bista1, Teresa A Brentnall, Mary P Bronner, Christopher J Langmead, Randall E Brand, Yang Liu.   

Abstract

BACKGROUND: Current surveillance guidelines for patients with long-standing ulcerative colitis (UC) recommend repeated colonoscopy with random biopsies, which is time-consuming, discomforting, and expensive. A less invasive strategy is to identify neoplasia by analyzing biomarkers from the more accessible rectum to predict the need for a full colonoscopy. The goal of this pilot study was to evaluate whether optical markers of rectal mucosa derived from a novel optical technique, partial-wave spectroscopic microscopy (PWS), could identify UC patients with high-grade dysplasia (HGD) or cancer (CA) present anywhere in their colon.
METHODS: Banked frozen nondysplastic mucosal rectal biopsies were used from 28 UC patients (15 without dysplasia and 13 with concurrent HGD or CA). The specimen slides were made using a touch prep method and underwent PWS analysis. We divided the patients into two groups: 13 as a training set and an independent 15 as a validation set.
RESULTS: We identified six optical markers, ranked by measuring the information gain with respect to the outcome of cancer. The most effective markers were selected by maximizing the cross-validated training accuracy of a Naive Bayes classifier. The optimal classifier was applied to the validation data yielding 100% sensitivity and 75% specificity.
CONCLUSIONS: Our results indicate that the PWS-derived optical markers can accurately predict UC patients with HGD/CA through assessment of rectal epithelial cells. By aiming for high sensitivity, our approach could potentially simplify the surveillance of UC patients and improve overall resource utilization by identifying patients with HGD/CA who should proceed with colonoscopy.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21351200      PMCID: PMC3139749          DOI: 10.1002/ibd.21639

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  30 in total

1.  Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis.

Authors:  K Holzmann; M Weis-Klemm; B Klump; C J Hsieh; F Borchard; M Gregor; R Porschen
Journal:  Scand J Gastroenterol       Date:  2001-12       Impact factor: 2.423

2.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  MGMT promoter methylation and field defect in sporadic colorectal cancer.

Authors:  Lanlan Shen; Yutaka Kondo; Gary L Rosner; Lianchun Xiao; Natalie Supunpong Hernandez; Jill Vilaythong; P Scott Houlihan; Robert S Krouse; Anil R Prasad; Janine G Einspahr; Julie Buckmeier; David S Alberts; Stanley R Hamilton; Jean-Pierre J Issa
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

5.  Family history as a risk factor for colorectal cancer in inflammatory bowel disease.

Authors:  J Askling; P W Dickman; P Karlén; O Broström; A Lapidus; R Löfberg; A Ekbom
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

Review 6.  Microscopic imaging and spectroscopy with scattered light.

Authors:  Nada N Boustany; Stephen A Boppart; Vadim Backman
Journal:  Annu Rev Biomed Eng       Date:  2010-08-15       Impact factor: 9.590

7.  Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis.

Authors:  Fumiaki Sato; Noam Harpaz; David Shibata; Yan Xu; Jing Yin; Yuriko Mori; Tong-Tong Zou; Suna Wang; Kena Desai; Anatoly Leytin; Florin M Selaru; John M Abraham; Stephen J Meltzer
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

8.  Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells.

Authors:  Hariharan Subramanian; Prabhakar Pradhan; Yang Liu; Ilker R Capoglu; Xu Li; Jeremy D Rogers; Alexander Heifetz; Dhananjay Kunte; Hemant K Roy; Allen Taflove; Vadim Backman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

9.  Proteins That Underlie Neoplastic Progression of Ulcerative Colitis.

Authors:  Teresa A Brentnall; Sheng Pan; Mary P Bronner; David A Crispin; Hamid Mirzaei; Kelly Cooke; Yasuko Tamura; Tatiana Nikolskaya; Lellean Jebailey; David R Goodlett; Martin McIntosh; Ruedi Aebersold; Peter S Rabinovitch; Ru Chen
Journal:  Proteomics Clin Appl       Date:  2009-09-14       Impact factor: 3.494

10.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

View more
  9 in total

Review 1.  Spectroscopic applications in gastrointestinal endoscopy.

Authors:  Hemant K Roy; Vadim Backman
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-08       Impact factor: 11.382

2.  Investigation of nuclear nano-morphology marker as a biomarker for cancer risk assessment using a mouse model.

Authors:  Rajan K Bista; Shikhar Uttam; Douglas J Hartman; Wei Qiu; Jian Yu; Lin Zhang; Randall E Brand; Yang Liu
Journal:  J Biomed Opt       Date:  2012-06       Impact factor: 3.170

3.  Nuclear nano-morphology markers of histologically normal cells detect the "field effect" of breast cancer.

Authors:  Rajan K Bista; Pin Wang; Rohit Bhargava; Shikhar Uttam; Douglas J Hartman; Randall E Brand; Yang Liu
Journal:  Breast Cancer Res Treat       Date:  2012-06-16       Impact factor: 4.872

4.  Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view.

Authors:  John B Kisiel; David A Ahlquist
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

5.  Colonoscopy and optical biopsy: bridging technological advances to clinical practice.

Authors:  Hemant K Roy; Michael J Goldberg; Shailesh Bajaj; Vadim Backman
Journal:  Gastroenterology       Date:  2011-04-24       Impact factor: 22.682

6.  Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens.

Authors:  Douglas J Hartman; Alyssa M Krasinskas; Shikhar Uttam; Kevin Staton; Rajan Bista; Sumera Rizvi; Adam Slivka; Randall Brand; Yang Liu
Journal:  Am J Clin Pathol       Date:  2014-06       Impact factor: 2.493

7.  Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis-associated neoplasia.

Authors:  Kiyoshi Hashimoto; Susumu Saigusa; Toshimitsu Araki; Koji Tanaka; Yoshiki Okita; Hiroyuki Fujikawa; Mikio Kawamura; Yoshinaga Okugawa; Yuji Toiyama; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Oncol Lett       Date:  2013-08-16       Impact factor: 2.967

8.  Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect".

Authors:  Kenneth E Fasanella; Rajan K Bista; Kevin Staton; Sumera Rizvi; Shikhar Uttam; Chengquan Zhao; Antonia Sepulveda; Randall E Brand; Kevin McGrath; Yang Liu
Journal:  J Cancer       Date:  2013-09-10       Impact factor: 4.207

9.  Investigation of depth-resolved nanoscale structural changes in regulated cell proliferation and chromatin decondensation.

Authors:  Shikhar Uttam; Rajan K Bista; Kevin Staton; Sergey Alexandrov; Serah Choi; Christopher J Bakkenist; Douglas J Hartman; Randall E Brand; Yang Liu
Journal:  Biomed Opt Express       Date:  2013-03-22       Impact factor: 3.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.